John R. Stanley, M.D.
Emeritus Professor of Dermatology
Department: Dermatology
Contact information
University of Pennsylvania School of Medicine
Department of Dermatology
421 Curie Boulevard
Philadelphia, PA 19104
Department of Dermatology
421 Curie Boulevard
Philadelphia, PA 19104
Education:
B.A. (Physics)
Cornell University, 1970.
M.D.
Harvard Medical School, 1974.
Permanent linkB.A. (Physics)
Cornell University, 1970.
M.D.
Harvard Medical School, 1974.
Selected Publications
Yoshida K, Ishii K, Shimizu A, Yokouchi M, Amagai M, Shiraishi K, Shirakata Y, Stanley JR, Ishiko A: Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering. J Dermatol Sci 85: 197-207, 2017.Chen J, Zheng Q, Hammers CM, Ellebrecht CT, Mukherjee EM, Tang HY, Lin C, Yuan H, Pan M, Langenhan J, Komorowski L, Siegel DL, Payne AS, Stanley JR: Proteomic analysis of pemphigus autoantibodies indicates a larger, more diverse, and more dynamic repertoire than determined by B-cell genetics. Cell Reports 18: 237-247, 2017.
Hammers CM, Stanley JR: Mechanisms of Disease: Pemphigus and bullous pemphigoid. Annual Review of Pathology: Mechanisms of Disease 11: 175-197, 2016.
Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, Stanley JR: Persistence of anti-desmoglein 3 IgG B-cell clones in pemphigus patients over years. J. Invest. Dermatol. 135: 742-749, 2015.
Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, Makni S, Turki H, Hachiya T, Kuroda K, Stanley JR, Masmoudi H, Amagai M: Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus. J Dermatol Sci doi: 10.1016/j.jdermsci.2013.02.002. Epub 2012 Feb 19, 70(1): 19-25 April 2013.
Kouno K, Lin C, Schechter N, Siegel D, Yang X, Seykora JT, Stanley JR: Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody. J Invest Dermatol February 2013 Notes: Advance online publication 4 April 2013; doi: 10.1038/jid.2013.85.
Hammers CM, Stanley JR: Antibody phage display: Technique and applications J. Invest. Dermatol. 134:e17(doi:10.1038/jid 2013.521), 2013.
Hammers CM, Stanley JR: Desmoglein-1, differentiation, and disease. J. Clin. Invest. Doi:10.1172/JCI69071, 2013.
Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS: Adjuvant rituximab therapy of pemphigus: A single center experience with 31 patients. Arch Dermatol 148: 1031-1036, 2012.
Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR: Homologous regions of heavy chain complementarity determining region 3 (H-CDR3) of pemphigus antibodies cause pathogenicity. J Clin Invest 120: 4111-4117, 2010.